IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced financial results for the three and six months ended June 30, 2007. “Product revenue for the first half of this year more than doubled compared with the first half of 2006, and we are tracking well against our 2007 product revenue guidance of $25 million to $29 million,” said Endologix President and Chief Executive Officer Paul McCormick. “We are very pleased with the productivity of our domestic sales force and continue to see significant growth opportunity in the U.S. market. We have recently promoted one member of our sales team and recruited two additional highly qualified professionals, increasing our regional sales managers to 10 in advance of our planned domestic sales force expansion to approximately 50 sales territories by 2007 year end.
